3.8 Article

Thalamic hemi-chorea: a rare complication after receiving the adenoviral vector-based COVID-19 vaccine: a case report

Journal

CLINICAL AND EXPERIMENTAL VACCINE RESEARCH
Volume 11, Issue 2, Pages 217-221

Publisher

KOREAN VACCINE SOC
DOI: 10.7774/cevr.2022.11.2.217

Keywords

SARS-CoV-2; COVID-19 vaccine; Thrombosis; Hemi-chorea; Lacunar stroke; Immunoglobulin G antibodies against platelet factor 4; Case report

Categories

Ask authors/readers for more resources

This case report presents a 72-year-old male who developed a thalamic stroke leading to uncontrollable movements due to vaccine-induced immune thrombocytopenia. The patient's symptoms appeared after receiving the vaccine, and improved gradually after treatment, highlighting the importance of clinicians' awareness in recognizing and managing this novel immune-mediated response.
Lacunar strokes occur when a branch of a large cerebral artery is blocked. The thalamus is often affected, causing uncontrollable motions. A 72-year-old previously healthy man presented with involuntary motions in the right limbs, which were present at rest, and exacerbated during voluntary actions. He had received the first dose of the adenoviral vector-based coronavirus disease 2019 vaccine (ChAdOx1 nCoV-19) 9 days ago. Severe thrombocytopenia and elevated levels of lactate dehydrogenase, ferritin, C-reactive protein, and D-dimer were found, without any evidence of connective tissue disease. Electromyography demonstrated typical choreiform movements, and the brain magnetic resonance imaging indicated a small high signal lesion on the left side of the thalamus. Detection of the immunoglobulin G antibodies against platelet factor 4 in the blood, negative heparin-induced platelet activation (HIPA) test, and positive modified HIPA test confirmed the thalamic stroke due to the vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). He was admitted to the intensive care unit and received nadroparin, sodium ozagrel, edaravone, methylprednisolone, and haloperidol. His hemi-chorea improved gradually over 2 weeks, and he was discharged after 21 days with rehabilitation advice. VIPIT due to the ChAdOx1 nCoV-19 is a novel immune-mediated response that needs clinicians' awareness and further investigations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available